Univest
Univest
  • Markets

Gaudium IVF and Women Health Share Price Target 2027: 24.7% Upside to Rs 129, Bull Rs 155

  • November 17, 2026
  • Posted by: Kunal Singla
  • Category: Market
No Comments
Gaudium IVF and Women Health Share Price Target 2027: 24.7% Upside to Rs 129, Bull Rs 155

Gaudium IVF and Women Health share price Rs 103.42 (17 November 2026). Base target Rs 129, bull Rs 155, downside risk Rs 86.1. PE 33.82. 52W range Rs 69.18 to Rs 163.18.

Quick Answer

The Gaudium IVF and Women Health share price target for 2027 is Rs 129, about 24.7% above the current price of Rs 103.42. The bull case is Rs 155, and the downside risk level, which is not a target, is Rs 86.1. The base case assumes earnings per share grow 20.0% a year, a cap applied because the FY24 to FY26 pace was 20.5%, with the stock holding its PE of 33.82. These are model-based estimates built from reported financials, not guaranteed outcomes.

Investors weighing a Gaudium IVF and Women Health target price for 2027 should start with where the stock sits today. At Rs 103.42 on 17 November 2026, it is 36.6% below its 52-week high of Rs 163.18 and 49.5% above its 52-week low of Rs 69.18. That range spans 136% from low to high, so the entry point matters as much as the Gaudium IVF and Women Health price forecast itself.

This article builds the Gaudium IVF and Women Health share price target from reported numbers only: five years of annual results, the last five quarters, the latest shareholding pattern and current valuation ratios from company filings and exchange data. Each scenario states its assumptions, so you can trace how the base case, the bull case and the downside risk level were reached and test them against your own view.

Click Here – Get Free Investment Predictions

Table of Contents

Toggle
  • Gaudium IVF and Women Health Stock Analysis: Company Overview and Key Stats
  • Why Is Gaudium IVF and Women Health Share Price Target Set at Rs 129 for 2027?
    • Earnings Growth Behind the Gaudium IVF and Women Health Target Price: Five Years of Results
    • Margins and the Latest Quarter
    • Balance Sheet and Cash Flow
    • Valuation Check for the Gaudium IVF and Women Health Stock Target: PE, Price to Book and ROE
    • Shareholding Pattern and Institutional Holding
  • Gaudium IVF and Women Health Share Price Targets for the Short Term and 12 Months
    • Short Term Gaudium IVF and Women Health Stock Target Levels: Technical Setup
    • 12 Month Gaudium IVF and Women Health Target Price for 2027
    • How EPS Growth and PE Multiple Change the Gaudium IVF and Women Health Target Price
  • Bull Case and Downside Risk for Gaudium IVF and Women Health Stock Target in 2027
    • Bull Case Rs 155
    • Downside Risk Level Rs 86.1
  • Key Risks to the Gaudium IVF and Women Health Target Price for 2027
    • Growth Slowdown Risk for the Gaudium IVF and Women Health Price Target
    • Liquidity and Size Risk
    • Valuation and Margin Risk
    • Market and Technical Risk
  • How to Invest in Gaudium IVF and Women Health
  • Conclusion
  • FAQs on Gaudium IVF and Women Health Share Price Target 2027
    • What is the Gaudium IVF and Women Health share price target for 2027?
    • What is the Gaudium IVF and Women Health share price today?
    • Is Gaudium IVF and Women Health a buy or sell at the current price?
    • What are the bull case target and downside risk level for Gaudium IVF and Women Health shares?
    • What are the main risks to the Gaudium IVF and Women Health price target?
    • What is the PE ratio of Gaudium IVF and Women Health and how does it compare with the industry?
    • Who owns Gaudium IVF and Women Health, and what is the promoter holding?
    • What were Gaudium IVF and Women Health’s latest quarterly results?

Gaudium IVF and Women Health Stock Analysis: Company Overview and Key Stats

Gaudium IVF and Women Health (NSE: GAUDIUMIVF) has a market capitalisation of Rs 783.00 crore. In FY26 it reported revenue of Rs 104.89 crore and net profit of Rs 24.49 crore. The table collects the figures the Gaudium IVF and Women Health share price target is built on.

Metric Value
Company Gaudium IVF and Women Health
NSE Ticker GAUDIUMIVF
CMP (17 November 2026) Rs 103.42
52-Week High Rs 163.18
52-Week Low Rs 69.18
Market Cap Rs 783.00 crore
PE Ratio (TTM) 33.82
Industry PE 62.11
Price to Book 5.14
Return on Equity 16.06%
Debt to Equity 0.16
EPS (TTM) Rs 3.18
Dividend Yield 0.00%
12-Month Base Target Rs 129
Bull Case Rs 155
Downside Risk Level (not a target) Rs 86.1

Why Is Gaudium IVF and Women Health Share Price Target Set at Rs 129 for 2027?

The arithmetic is short. Trailing EPS of Rs 3.18 grown for one year gives a forward EPS estimate of Rs 3.82, and multiplying it by the unchanged PE of 33.82 gives the Rs 129 base-case Gaudium IVF and Women Health stock target. The bull case adds faster earnings growth and a higher multiple, while the downside risk level assumes flat earnings and a lower multiple.

Earnings Growth Behind the Gaudium IVF and Women Health Target Price: Five Years of Results

Gaudium IVF and Women Health grew revenue from Rs 36.52 crore in FY22 to Rs 104.89 crore in FY26, a compound annual growth rate of 30.2%. Net profit grew more slowly, from Rs 8.83 crore to Rs 24.49 crore (29.0% a year), which points to margin pressure alongside the sales growth.

Financial Year Revenue (Rs Cr) Net Profit (Rs Cr) EPS (Rs) Dividend per Share (Rs)
FY22 36.52 8.83 1.44 0.00
FY23 44.26 13.52 2.20 0.00
FY24 53.75 16.60 2.70 0.00
FY25 70.96 19.18 3.12 0.00
FY26 104.89 24.49 3.92 0.00

FY26 revenue growth was 47.8%, faster than the four-year average of 30.2%, and net profit moved up 27.7%. EPS rose from Rs 2.70 in FY24 to Rs 3.92 in FY26. The FY27 outlook for the Gaudium IVF and Women Health price target depends on whether that EPS estimate keeps compounding.

Margins and the Latest Quarter

Gaudium IVF and Women Health converted 23.3% of FY26 revenue into net profit, against 27.0% in FY25, within a five-year range of 23.3% to 30.9%. EBITDA margin was 36.5% in FY26 versus 40.7% in FY25.

In the September 2026 quarter, revenue was Rs 38.50 crore, up 20.8% from the same quarter a year earlier, while net profit of Rs 9.41 crore was up 0.3%. EBITDA came in at Rs 14.56 crore, up 4.7% year on year. The next quarterly result is the first test of whether the earnings assumption behind the Gaudium IVF and Women Health stock target holds.

Balance Sheet and Cash Flow

Debt to equity stands at 0.16, and shareholders’ equity grew from Rs 9.29 crore in FY22 to Rs 152.30 crore in FY26. Operating cash flow in FY26 was Rs 7.25 crore against capital expenditure of Rs 6.72 crore, leaving free cash flow of Rs 0.53 crore, or 0.1% of the current market capitalisation. In FY25 free cash flow was negative at Rs 0.16 crore, so cash generation has not been steady year to year.

Valuation Check for the Gaudium IVF and Women Health Stock Target: PE, Price to Book and ROE

At a PE of 33.82 against an industry PE of 62.11, Gaudium IVF and Women Health trades at a discount to its industry. Price to book is 5.14 on a book value of Rs 20.92 per share, and return on equity is 16.06%. A PE of 33.82 equals an earnings yield of 3.0%, and the FY26 dividend of Rs 0.00 per share gives a yield of 0.00%.

Shareholding Pattern and Institutional Holding

Promoters held 71.29% of Gaudium IVF and Women Health in September 2026, and promoter holding fell from 99.98% in September 2025 to 71.29% in September 2026. Foreign institutional investors (FII) held 1.19% and domestic institutions (DII) held 2.22%, which puts total institutional holding at 3.41%. FII holding rose from 0.00% in September 2025 to 1.19% in September 2026. Public shareholders own the remaining 25.29%. Institutional holding this low means the stock sees limited professional coverage, and price moves can be sharper when trading volumes are thin.

Gaudium IVF and Women Health Share Price Targets for the Short Term and 12 Months

Short Term Gaudium IVF and Women Health Stock Target Levels: Technical Setup

At Rs 103.42 on 17 November 2026, Gaudium IVF and Women Health trades below its 50-day simple moving average of Rs 108.05 and below its 200-day exponential moving average of Rs 106.60. The 14-day RSI reads 56.1, which is neutral territory, and the MACD line sits above its signal line. The nearest resistance level is Rs 106.60 (200-day exponential moving average) and the nearest support is Rs 69.18 (52-week low). A sustained move above Rs 106.60 would improve the short-term setup, while a close below Rs 69.18 would shift attention to the next support.

12 Month Gaudium IVF and Women Health Target Price for 2027

The 12-month target of Rs 129 means a move of 24.7% up from Rs 103.42 over the next 12 months. It would still leave the stock 20.9% below its 52-week high of Rs 163.18. Anyone checking the Gaudium IVF and Women Health share price target against their own view should focus on two inputs: the EPS estimate and the PE multiple.

How EPS Growth and PE Multiple Change the Gaudium IVF and Women Health Target Price

EPS Growth PE 27.06 PE 33.82 PE 38.89
0.0% (EPS Rs 3.18) Rs 86.1 Rs 108 Rs 124
20.0% (EPS Rs 3.82) Rs 103 Rs 129 Rs 149
25.0% (EPS Rs 3.98) Rs 108 Rs 135 Rs 155

Each cell multiplies the forward EPS estimate by the PE shown. Reading across a row shows what a de-rating or re-rating does to the Gaudium IVF and Women Health price forecast, and reading down a column shows what earnings growth is worth at a fixed multiple.

Bull Case and Downside Risk for Gaudium IVF and Women Health Stock Target in 2027

Bull Case Rs 155

The bull case Gaudium IVF and Women Health price target needs EPS growth of 25.0%, which lifts forward EPS to Rs 3.98, and a PE multiple that rises 15% to 38.89. That gives Rs 155, 49.9% above the current price and below the 52-week high of Rs 163.18.

Downside Risk Level Rs 86.1

The downside risk level is not a target. It assumes EPS stays flat at Rs 3.18 and the PE falls 20% to 27.06. That gives Rs 86.1, 16.7% below the current price and above the 52-week low of Rs 69.18.

Scenario EPS Growth PE Multiple Price (Rs) Change vs CMP
Bull Case 25.0% 38.89 Rs 155 +49.9%
Base Case 20.0% 33.82 Rs 129 +24.7%
Downside Risk 0.0% 27.06 Rs 86.1 -16.7%

Key Risks to the Gaudium IVF and Women Health Target Price for 2027

Growth Slowdown Risk for the Gaudium IVF and Women Health Price Target

Revenue in the September 2026 quarter was up 20.8% year on year, and FY26 revenue growth was 47.8%. If growth slows from here, the EPS estimate behind the Gaudium IVF and Women Health stock target will need revising.

Liquidity and Size Risk

Gaudium IVF and Women Health has a market capitalisation of Rs 783.00 crore. Institutional holding is 3.41%, and promoters hold 71.29%. Stocks of this size can move sharply on small volumes, and exits can take longer than entries.

Valuation and Margin Risk

Net margin was 23.3% in FY26, and a squeeze from higher costs or weaker pricing would hit earnings first. At a PE of 33.82 versus an industry PE of 62.11, a de-rating toward the downside-risk PE of 27.06 would cut the price even if earnings hold.

Market and Technical Risk

Technical indicators add short-term risk: the 14-day RSI is 56.1 and the MACD sits above its signal line. A broad fall in the Nifty 50 or the Sensex can override company fundamentals for weeks at a time. Treat every Gaudium IVF and Women Health share price target as a range of outcomes rather than a single point.

How to Invest in Gaudium IVF and Women Health

Start with the live price and volume. Any Gaudium IVF and Women Health share price target is only as current as the data behind it, and the data here is as of 17 November 2026, so refresh the Rs 103.42 price before acting on any level.

Next, review the fundamentals yourself. The Univest Screener lets you check Gaudium IVF and Women Health’s PE, ROE, debt and shareholding in one place.

Check Gaudium IVF and Women Health fundamentals on the Univest Screener

Then compare the three Gaudium IVF and Women Health target price scenarios with your own view. If you expect EPS growth below 20.0%, the base case is too optimistic for you; if you expect more, the bull case deserves weight.

Decide your position size and exit levels before you buy. The support and resistance levels above can serve as reference points, but they are not recommendations.

Finally, place the order through a SEBI-registered broker or the Univest app, and review the position after each quarterly result. Consult a SEBI-registered advisor if you are unsure.

Download the Univest iOS App or Univest Android App to track Gaudium IVF and Women Health live price and get daily stock recommendations.

Conclusion

The Gaudium IVF and Women Health share price target for 2027 is Rs 129 in the base case, with Rs 155 as the bull case. The support for that view is arithmetic you can check: EPS grew 20.5% a year over FY24 to FY26, and the stock trades at a PE of 33.82. The risks are equally concrete, including institutional holding of only 3.41% and a downside scenario that cuts the price 17% if earnings stall. Use these numbers as a framework for judging the Gaudium IVF and Women Health price target, check them against the latest filings, and size any position to your own risk appetite.

Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).

FAQs on Gaudium IVF and Women Health Share Price Target 2027

What is the Gaudium IVF and Women Health share price target for 2027?

Ans. The base-case Gaudium IVF and Women Health share price target for 2027 is Rs 129, which is 24.7% above the price of Rs 103.42 on 17 November 2026. The bull case is Rs 155 and the downside risk level, which is not a target, is Rs 86.1. All three come from one method: forward EPS multiplied by a PE multiple, using only reported results. They are model estimates and not guaranteed outcomes, and the next quarterly result is the first check on the EPS assumption.

What is the Gaudium IVF and Women Health share price today?

Ans. As of 17 November 2026, before market open, Gaudium IVF and Women Health (NSE: GAUDIUMIVF) is quoted at Rs 103.42, which is its last closing price from the previous session. That is 36.6% below the 52-week high of Rs 163.18 and 49.5% above the 52-week low of Rs 69.18. The market capitalisation of Rs 783.00 crore places it among small-cap stocks. Prices change through the trading session, so check the live quote before acting on any level in this article.

Is Gaudium IVF and Women Health a buy or sell at the current price?

Ans. The data points both ways. On the positive side, EPS has grown 20.5% a year over FY24 to FY26 and the base case implies 24.7% upside; on the cautious side, institutional holding is only 3.41%, and the downside risk level of Rs 86.1 is 17% below the current price. Whether Gaudium IVF and Women Health fits your portfolio depends on your time horizon, position size and risk appetite. Consult a SEBI-registered advisor before investing, as this article is not investment advice.

What are the bull case target and downside risk level for Gaudium IVF and Women Health shares?

Ans. The bull case in the Gaudium IVF and Women Health share price target for 2027 is Rs 155, which assumes 25.0% EPS growth and a PE of 38.89, a 15% re-rating from today’s multiple. That is 49.9% above the current price and below the 52-week high of Rs 163.18. The downside risk level is Rs 86.1, which assumes flat EPS and a PE of 27.06, 20% lower than today. It sits 16.7% below the current price and above the 52-week low of Rs 69.18, and it marks a risk to watch, not a target.

What are the main risks to the Gaudium IVF and Women Health price target?

Ans. Four risks matter most for the Gaudium IVF and Women Health share price target: slower revenue or profit growth, a PE de-rating, thin liquidity or size risk, and weakness in the broader market. With a market capitalisation of Rs 783.00 crore, the stock can move sharply on small volumes, and exits can take longer than entries. A fall to the downside-risk PE of 27.06 would cut the price even if earnings hold.

What is the PE ratio of Gaudium IVF and Women Health and how does it compare with the industry?

Ans. The PE ratio of Gaudium IVF and Women Health is 33.82, against an industry PE of 62.11, which is a discount to the industry. Price to book is 5.14 and return on equity is 16.06%, and the PE equals an earnings yield of 3.0%. The base case holds the PE unchanged, so the Gaudium IVF and Women Health share price target moves only with earnings, while the bull and downside scenarios change the multiple by +15% and -20%.

Who owns Gaudium IVF and Women Health, and what is the promoter holding?

Ans. Promoters held 71.29% of Gaudium IVF and Women Health in September 2026. FII held 1.19%, DII held 2.22% and the public held 25.29%. Together the two institutional groups hold 3.41%. Shareholding is filed every quarter, so it is worth rechecking after each result.

What were Gaudium IVF and Women Health’s latest quarterly results?

Ans. In the September 2026 quarter, Gaudium IVF and Women Health reported revenue of Rs 38.50 crore (up 20.8% year on year) and net profit of Rs 9.41 crore (up 0.3%). For comparison, FY26 full-year revenue growth was 47.8% and net profit moved up 27.7%. Each new quarter either supports or weakens the EPS growth of 20.0% assumed in the base case.



Stock Market
Author: Kunal Singla
Kunal Singla is the Associate Director - Research at Univest, leading quantitative equity research, intraday trading setups, and derivatives strategy. With 4+ years of experience in Indian equity markets, he combines rigorous quantitative methods with classical technical analysis to build high-conviction research frameworks for retail and advisory clients. He holds an MSc from the Indian Institute of Technology (IIT) Delhi — one of India's most selective institutions — and has completed the Certificate in Quantitative Finance (CQF), a globally recognised programme covering derivatives pricing, risk modelling, machine learning for finance, and advanced portfolio theory. This combination places him in a small group of Indian analysts with both deep academic training in quantitative methods and SEBI-recognised research credentials. Kunal holds seven SEBI-recognised NISM certifications spanning research, derivatives, portfolio management, and securities operations: Series-XV (Research Analyst), Series-XXI-A (Portfolio Managers), Series-XVI (Commodity Derivatives), Series-VIII (Equity Derivatives), Series-VII (SORM), Series-V-A (Mutual Fund Distributors), and Series-I (Currency Derivatives). At Univest — India's SEBI-registered research and advisory platform — Kunal leads research inputs for Pro Lite, Pro Super, Pro Gold, and Pro Commodity advisory services, alongside publishing intraday stock picks on Univest Blogs.

Leave a Reply Cancel reply